Drugs / BI 3034701
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07708493 | Jul → Oct 2026 expected | — | Boehringer Ingelheim | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07693231 | Jul → Dec 2026 expected | obesity disorder | Boehringer Ingelheim | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06352437 | Jun 2024 → Oct 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07662122 | Jun 2026 → Aug 2027 expected | obesity disorder | Boehringer Ingelheim | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 3034701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07708493 ↗ |
| Route | Subcutaneous | “injection under the skin” NCT06352437 ↗ |